Patents by Inventor Gusti Zeiner
Gusti Zeiner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190247434Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), and RNA control devices, combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. RDEs can be combined with RNA control devices to make RDEs that include ligand mediated control. These smart RDEs and other RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell.Type: ApplicationFiled: February 11, 2019Publication date: August 15, 2019Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner, Krista McNally
-
Patent number: 10323249Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.Type: GrantFiled: October 3, 2018Date of Patent: June 18, 2019Assignee: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Patent number: 10323248Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.Type: GrantFiled: August 31, 2017Date of Patent: June 18, 2019Assignee: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Publication number: 20190178870Abstract: The present invention relates generally to the field of making novel antigen binding domains against infectious diseases. The present invention also relates to novel CARs that utilize the novel antigen binding domains as an extracellular element. The present invention also relates to use of the novel antigen binding domains as therapeutic agents.Type: ApplicationFiled: February 14, 2019Publication date: June 13, 2019Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Patent number: 10222369Abstract: The present invention relates generally to the field of making novel antigen binding domains against infectious diseases. The present invention also relates to novel CARs that utilize the novel antigen binding domains as an extracellular element. The present invention also relates to use of the novel antigen binding domains as therapeutic agents.Type: GrantFiled: May 16, 2017Date of Patent: March 5, 2019Assignee: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Publication number: 20190024095Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.Type: ApplicationFiled: October 3, 2018Publication date: January 24, 2019Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Publication number: 20180142031Abstract: The present invention relates generally to the field of RNA Control Devices and/or destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) in eukaryotic cells. The present invention also relates to split CARs (Side-CARs) in eukaryotic cells. More specifically, the present invention relates to DEs, RNA Control Devices, and/or side-CARs combined with Chimeric Antigen Receptors to make small molecule actuatable CAR polypeptides. The present invention also relates to DE-CARs, Smart CARs (Smart=small molecule actuatable RNA trigger), Smart-DE-CARs, and/or Side-CARs for use in the treatment of disease.Type: ApplicationFiled: December 21, 2017Publication date: May 24, 2018Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Publication number: 20180127776Abstract: In an aspect, the present invention relates generally to RNA control devices, destabilizing elements (“DE”), Solute Carrier Transporters (“SLC”), and/or control regions where some or all of these control elements are ligand matched. In another aspect, the present invention relates to ligand matched control regions, SLCs and/or control devices that produce control systems with desired properties. In a further aspect, the present invention relates to use of these control systems to control expression of transgenes in eukaryotic cells including, for example, stem cells, hematopoietic cells, and host cells for gene therapy.Type: ApplicationFiled: November 1, 2017Publication date: May 10, 2018Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Publication number: 20180057822Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.Type: ApplicationFiled: August 31, 2017Publication date: March 1, 2018Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Publication number: 20180030143Abstract: The present invention relates generally to the field of RNA Control Devices and/or destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) in eukaryotic cells. The present invention also relates to split CARs (Side-CARs) in eukaryotic cells. More specifically, the present invention relates to DEs, RNA Control Devices, and/or side-CARs combined with Chimeric Antigen Receptors to make small molecule actuatable CAR polypeptides. The present invention also relates to DE-CARs, Smart CARs (Smart=small molecule actuatable RNA trigger), Smart-DE-CARs, and/or Side-CARs for use in the treatment of disease.Type: ApplicationFiled: September 18, 2017Publication date: February 1, 2018Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Patent number: 9873907Abstract: A method for fragmenting a genome is provided. In certain embodiments, the method comprises: (a) combining a genomic sample containing genomic DNA with a plurality of Cas9-gRNA complexes, wherein the Cas9-gRNA complexes comprise a Cas9 protein and a set of at least 10 Cas9-associated guide RNAs that are complementary to different, pre-defined, sites in a genome, to produce a reaction mixture; and (b) incubating the reaction mixture to produce at least 5 fragments of the genomic DNA. Also provided is a composition comprising at least 100 Cas9-associated guide RNAs that are each complementary to a different, pre-defined, site in a genome. Kits for performing the method are also provided. In addition, other methods, compositions and kits for manipulating nucleic acids are also provided.Type: GrantFiled: May 29, 2014Date of Patent: January 23, 2018Assignee: Agilent Technologies, Inc.Inventors: Gusti Zeiner, Derek Lee Lindstrom, Brian Jon Peter, Robert A. Ach
-
Publication number: 20170336393Abstract: The present invention relates generally to the field of making novel antigen binding domains against infectious diseases. The present invention also relates to novel CARs that utilize the novel antigen binding domains as an extracellular element. The present invention also relates to use of the novel antigen binding domains as therapeutic agents.Type: ApplicationFiled: May 16, 2017Publication date: November 23, 2017Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Patent number: 9777064Abstract: The present invention relates generally to the field of RNA Control Devices and/or destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) in eukaryotic cells. The present invention also relates to split CARs (Side-CARs) in eukaryotic cells. More specifically, the present invention relates to DEs, RNA Control Devices, and/or side-CARs combined with Chimeric Antigen Receptors to make small molecule actuatable CAR polypeptides. The present invention also relates to DE-CARs, Smart CARs (Smart=small molecule actuatable RNA trigger), Smart-DE-CARs, and/or Side-CARs for use in the treatment of disease.Type: GrantFiled: March 15, 2016Date of Patent: October 3, 2017Assignee: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Publication number: 20170157176Abstract: In an aspect, the present invention relates generally to the field of treating disease with CAR devices, Smart CAR devices, DE CAR devices, and/or Smart-DE CAR devices. The present invention also relates generally to the genetic modification of cytotoxic T-lymphocytes to reduce target cell killing by apoptosis and/or increase production of lytic proteins at desired times. In an aspect, the invention relates to the use of these genetically modified T-lymphocytes and/or natural killer cells with CAR devices, Smart CAR devices, DE CAR devices, and/or Smart-DE CAR devices to enhance the immune response against a disease.Type: ApplicationFiled: December 5, 2016Publication date: June 8, 2017Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Publication number: 20170058298Abstract: The present invention relates to guide RNAs comprising adaptor segments having one or more modifications, and their use in homologous recombination by CRISPR:Cas systems. The modified adaptor segments are resistant to degradation by RNaseH. The present invention also relates to a dual guide RNA strategy in which a first guide RNA directs a Cas enzyme to make a double-strand break at a first target sequence, and a second guide RNA comprises an adaptor segment attached to a donor polynucleotide, and binds a second target sequence that is offset from the first target sequence.Type: ApplicationFiled: August 30, 2016Publication date: March 2, 2017Inventors: Andrew Kennedy, Gusti Zeiner, Subhadeep Roy, Chong Wing Yung
-
Publication number: 20160272718Abstract: The present invention relates generally to the field of RNA Control Devices and/or destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) in eukaryotic cells. The present invention also relates to split CARs (Side-CARs) in eukaryotic cells. More specifically, the present invention relates to DEs, RNA Control Devices, and/or side-CARs combined with Chimeric Antigen Receptors to make small molecule actuatable CAR polypeptides. The present invention also relates to DE-CARs, Smart CARs (Smart=small molecule actuatable RNA trigger), Smart-DE-CARs, and/or Side-CARs for use in the treatment of disease.Type: ApplicationFiled: March 15, 2016Publication date: September 22, 2016Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Patent number: 9163329Abstract: A method of sample analysis is provided. In certain embodiments, the method involves: a) obtaining a fragmented RNA sample comprising fragments of long RNA molecules and short RNA molecules; b) ligating an adaptor to an end of the RNA of the fragmented RNA sample to produce an adaptor-ligated sample; c) hybridizing said adaptor-ligated sample to an array of nucleic acid probes; and d) reading said array to obtain an estimate of the abundance of a long RNA in the RNA sample and an estimate of the abundance a small RNA in the RNA sample.Type: GrantFiled: January 19, 2012Date of Patent: October 20, 2015Assignee: Agilent Technologies, Inc.Inventors: Emily Marine Leproust, Gusti Zeiner, Petula N. D'andrade
-
Patent number: 9102936Abstract: A method of processing a target RNA is provided. In certain embodiments, this method comprises: contacting the products of an RNA ligase-mediated ligation reaction with an CAS6 protein, wherein: (i) the RNA ligase-mediated ligation reaction comprises: a target RNA, an RNA ligase, and first and second adaptors that can ligate together to produce an adaptor dimer that contains a CRISPR stem loop; and (ii) the CAS6 protein recognizes the CRISPR stem loop; thereby preventing the adaptor dimer from being reverse transcribed.Type: GrantFiled: May 15, 2013Date of Patent: August 11, 2015Assignee: Agilent Technologies, Inc.Inventors: Gusti Zeiner, Laurakay Bruhn
-
Patent number: 9074203Abstract: A method of processing an RNA sample is provided. In certain embodiments, the method may comprise: a) obtaining a fragmented RNA sample comprising: i. RNA fragments of long RNA molecules; and ii. unfragmented short RNA; and b) contacting said fragmented RNA sample with a first adaptor in the presence of a RtcB ligase, thereby producing a ligated RNA sample comprising adaptor-ligated fragments of long RNA. A kit for performing the method is also provided.Type: GrantFiled: February 8, 2012Date of Patent: July 7, 2015Assignee: Agilent Technologies, Inc.Inventors: Gusti Zeiner, Robert A. Ach
-
Patent number: 8927245Abstract: Provided herein is a method of preparing an RNA sample comprising: a) obtaining an RNA sample comprising: i. long RNA molecules that may be unfragmented or fragmented to contain 5?-OH group and a 2?-3?-cyclic phosphate group; and ii. short RNA molecules that comprise a 5? phosphate group and a 3? OH group; and b) contacting the RNA sample with an adaptor comprising either a 2?-PO group and 3?-OH group or a 2?,3?-cyclic phosphate group in the presence of a eukaryotic tRNA ligase, thereby producing a ligated RNA sample in which a) the short RNA molecules are selectively ligated to the adaptor or b) the short RNA molecules and long RNA fragments are selectively ligated to the adaptor.Type: GrantFiled: December 15, 2011Date of Patent: January 6, 2015Assignee: Agilent Technologies, Inc.Inventors: Gusti Zeiner, Robert A. Ach